Information  X 
Enter a valid email address

Vectura Group plc (VEC)

  Print      Mail a friend       Annual reports

Wednesday 11 April, 2012

Vectura Group plc

Notice of Results

RNS Number : 0642B
Vectura Group plc
11 April 2012

Notice of Results



Chippenham, UK - 11 April, 2012: Vectura Group plc (LSE: VEC), the Company that specialises in developing inhaled therapies for the treatment of respiratory diseases, will be announcing its preliminary results for the year ended 31 March 2012 on Thursday 26 April 2012. A webcast of the event will be available on the Company's website at


- Ends -





Vectura Group plc 

+44 (0)1249 667700

Julia Wilson, Director of Investor Relations





About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.


Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).


Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.  For further information, please visit Vectura's website at


This information is provided by RNS
The company news service from the London Stock Exchange